Evidence map›Paper›PMID 37221626›Full record

ArticleJournal of translational medicine2023

The Swedish childhood tumor biobank: systematic collection and molecular characterization of all pediatric CNS and other solid tumors in Sweden.

Teresita Díaz de Ståhl, Alia Shamikh, Markus Mayrhofer, Szilvester Juhos, Elisa Basmaci, Gabriela Prochazka, Maxime Garcia, Praveen Raj Somarajan, Katarzyna Zielinska-Chomej, Christopher Illies and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 1 country.

Teresita Díaz de StåhlDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. teresita.diaz.de.stahl@ki.se.ORCID 0000-0001-5933-6623
Alia ShamikhDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Markus MayrhoferDepartment of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Szilvester JuhosDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Elisa BasmaciDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Gabriela ProchazkaDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Maxime GarciaDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Praveen Raj SomarajanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Katarzyna Zielinska-ChomejDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Christopher IlliesDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Ingrid ØraDepartment of Paediatric Haematology Oncology and Immunology, Skåne University Hospital Lund, Lund, Sweden.
Peter SiesjöDepartment of Clinical Sciences Lund, Department of Neurosurgery, Lund University, Skåne University Hospital, Lund, Sweden.
Per-Erik SandströmDepartment of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.
Jakob StenmanChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Magnus SabelChildhood Cancer Centre, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.
Bengt GustavssonDepartment of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
Per KognerChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Susan PfeiferPediatric Hematology/Oncology, Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Gustaf LjungmanPediatric Hematology/Oncology, Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Johanna SandgrenDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Monica NistérDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEUppsala University · SELund University · SESahlgrenska University Hospital · SESkåne University Hospital · SEUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Swedish Childhood Tumor Biobank (BTB) is a nonprofit national infrastructure for collecting tissue samples and genomic data from pediatric patients diagnosed with central nervous system (CNS) and other solid tumors. The BTB is built on a multidisciplinary network established to provide the scientific community with standardized biospecimens and genomic data, thereby improving knowledge of the biology, treatment and outcome of childhood tumors. As of 2022, over 1100 fresh-frozen tumor samples are available for researchers. We present the workflow of the BTB from sample collection and processing to the generation of genomic data and services offered. To determine the research and clinical utility of the data, we performed bioinformatics analyses on next-generation sequencing (NGS) data obtained from a subset of 82 brain tumors and patient blood-derived DNA combined with methylation profiling to enhance the diagnostic accuracy and identified germline and somatic alterations with potential biological or clinical significance. The BTB procedures for collection, processing, sequencing, and bioinformatics deliver high-quality data. We observed that the findings could impact patient management by confirming or clarifying the diagnosis in 79 of the 82 tumors and detecting known or likely driver mutations in 68 of 79 patients. In addition to revealing known mutations in a broad spectrum of genes implicated in pediatric cancer, we discovered numerous alterations that may represent novel driver events and specific tumor entities. In summary, these examples reveal the power of NGS to identify a wide number of actionable gene alterations. Making the power of NGS available in healthcare is a challenging task requiring the integration of the work of clinical specialists and cancer biologists; this approach requires a dedicated infrastructure, as exemplified here by the BTB.

Indexed as

Biological Specimen BanksBrain NeoplasmsCentral Nervous SystemChildGenomicsHumansSwedenBiobankBioinformaticsChildhood cancerGenomicMethylationMutationNext generation sequence

Identifiers

PMID37221626
PMCPMC10204274
OpenAlexW4377821384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.